View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsIBEX Technologies 将来の成長Future 基準チェック /06現在、 IBEX Technologiesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長22.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Dec 15IBEX Technologies Inc. Provides Earnings Guidance for the Fiscal Year 2024IBEX Technologies Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the fiscal year 2023 range, with continued strong growth in the hemostasis business. Earnings before tax to be in line with the fiscal year 2023.すべての更新を表示Recent updatesお知らせ • Apr 12The Common Shares of IBEX Technologies to Be Delisted from TSX Venture Exchange, in Connection with the Completion of the Amalgamation and Effective at the Close of Business on April 11, 2024TSX Venture Exchange has accepted for filing an acquisition agreement dated February 9, 2024 between IBEX Technologies Inc. (the Company) and an arm's length third party (the "Acquirer") pursuant to which the Acquirer acquired all of the issued and outstanding common shares of the Company by way of an amalgamation under the Canada Business Corporations Act (the "CBCA") (the "Amalgamation"). In connection with the completion of the Amalgamation and effective at the close of business on April 11, 2024, the common shares of the Company will be delisted from TSX Venture Exchange.お知らせ • Apr 09+ 1 more updateBBI Solutions OEM Limited completed the acquisition of IBEX Technologies Inc. (TSXV:IBT) from Milfam LLC, McLean Capital Inc., Paul Baehr and others.BBI Solutions OEM Limited entered into a binding acquisition agreement to acquire IBEX Technologies Inc. (TSXV:IBT) from Milfam LLC, McLean Capital Inc., Paul Baehr and others for CAD 35.5 million on February 9, 2024. BBI will acquire all of the issued and outstanding shares of IBEX at a price of CAD 1.45 per share in cash. Under the amalgamation, each issued and outstanding common share of IBEX will be exchanged for one redeemable preferred share of Amalco, which will immediately be redeemed for CAD 1.45 cash per share. The total consideration is approximately CAD 37.9 million. Upon completion of the amalgamation, shareholders will cease to hold shares of IBEX and IBEX will be delisted from the TSX Venture Exchange. If BBI Solutions termination fee event occurs pursuant to Section 9.2(c)(i) of the acquisition agreement, the BBI Solutions shall pay IBEX the termination fee of CAD 0.97 million and if IBEX termination fee event occurs, IBEX shall pay the BBI Solutions the termination fee of CAD 1.894 million to BBI Solutions in accordance with Section 10.2(b) of the acquisition agreement. The amalgamation is subject to approval by at least two-thirds of the votes cast by IBEX shareholders present in person or represented by proxy and entitled to vote at the Meeting and is subject to third party approval. The Board of Directors of IBEX, after consultation with its financial and legal advisors, has unanimously approved entering into the acquisition agreement. Paul Baehr, Chairman, President and Chief Executive Officer of IBEX, and all of IBEX’s other directors and senior officers, holding in the aggregate approximately 10.39% of IBEX’s outstanding shares, have entered into Support and Voting Agreements with the Purchaser under which they have each agreed irrevocably to support and vote their shares in favour of the amalgamation. In addition, McLean Capital Inc. of Laval, Québec, and entities managed and advised by MILFAM LLC, holding in the aggregate approximately 36.76% of IBEX’s outstanding shares, have entered into similar Support and Voting Agreements with the Purchaser under which they have each agreed irrevocably to support and vote their shares in favour of the Amalgamation. As a result, shareholders holding in the aggregate approximately 47.15% of IBEX’s outstanding shares have entered into Support and Voting Agreements with the Purchaser. The amalgamation was approved by IBEX shareholders at an annual and special meeting held on April 3, 2024. Closing of the amalgamation is expected to take place on April 8, 2024.Fort Capital Partners provided a fairness opinion to the Board of Directors of IBEX in connection with the Amalgamation. Laurel Hill Advisory Group has been retained as IBEX’s shareholder communications advisor and will receive a fee of CAD 0.05 million for its services. Fasken Martineau DuMoulin LLP is acting as legal counsel to IBEX in connection with the amalgamation. Computershare Investor Services Inc. acted as depositary and transfer agent to IBEX.BBI Solutions OEM Limited completed the acquisition of IBEX Technologies Inc. (TSXV:IBT) from Milfam LLC, McLean Capital Inc., Paul Baehr and others on April 8, 2024. In connection with the sale, IBEX has applied for delisting from the TSX Venture Exchange, which is expected to occur on or about April 11, 2024.お知らせ • Mar 25IBEX Technologies Provides Delisting UpdateIBEX Technologies Inc. has entered into an agreement for the sale of the company. Subject to shareholder approval on April 3, 2024, the transaction is expected to close on April 8, 2024, following which the company will be delisted from the TSX Venture Exchange.お知らせ • Feb 14+ 1 more updateIBEX Technologies to Delist from TSX-VIBEX Technologies Inc, has announced that it has entered into a binding acquisition agreement dated February 9, 2024 (the "Acquisition Agreement") and related agreements with 15720273 Canada Inc. (the "Purchaser"), a newly incorporated, wholly-owned subsidiary of BBI Solutions OEM Limited ("BBI"), whereby BBI will acquire all of the issued and outstanding shares of IBEX at a price of $1.45 per share in cash. Upon completion of the Amalgamation, shareholders will cease to hold shares of IBEX and IBEX will be delisted from the TSX Venture Exchange.Reported Earnings • Dec 15First quarter 2024 earnings released: EPS: CA$0.03 (vs CA$0.03 in 1Q 2023)First quarter 2024 results: EPS: CA$0.03 (in line with 1Q 2023). Revenue: CA$2.06m (up 18% from 1Q 2023). Net income: CA$810.3k (up 19% from 1Q 2023). Profit margin: 39% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Dec 15IBEX Technologies Inc. Provides Earnings Guidance for the Fiscal Year 2024IBEX Technologies Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the fiscal year 2023 range, with continued strong growth in the hemostasis business. Earnings before tax to be in line with the fiscal year 2023.お知らせ • Nov 18IBEX Technologies Inc., Annual General Meeting, Jan 24, 2024IBEX Technologies Inc., Annual General Meeting, Jan 24, 2024.Reported Earnings • Nov 10Full year 2023 earnings released: EPS: CA$0.16 (vs CA$0.067 in FY 2022)Full year 2023 results: EPS: CA$0.16 (up from CA$0.067 in FY 2022). Revenue: CA$7.49m (down 5.1% from FY 2022). Net income: CA$3.89m (up 133% from FY 2022). Profit margin: 52% (up from 21% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Jun 09New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 26% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (26% accrual ratio). Minor Risk Market cap is less than US$100m (€16.4m market cap, or US$17.7m).Reported Earnings • Jun 08Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.02 in 3Q 2022)Third quarter 2023 results: EPS: CA$0.03 (up from CA$0.02 in 3Q 2022). Revenue: CA$2.26m (up 2.5% from 3Q 2022). Net income: CA$891.4k (up 56% from 3Q 2022). Profit margin: 39% (up from 26% in 3Q 2022). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 59% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Mar 21Second quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.02 in 2Q 2022)Second quarter 2023 results: EPS: CA$0.003 (down from CA$0.02 in 2Q 2022). Revenue: CA$1.72m (down 6.0% from 2Q 2022). Net income: CA$100.0k (down 75% from 2Q 2022). Profit margin: 5.8% (down from 22% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has increased by 105% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Dec 16First quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.03 in 1Q 2022)First quarter 2023 results: EPS: CA$0.03 (in line with 1Q 2022). Revenue: CA$1.75m (down 1.7% from 1Q 2022). Net income: CA$678.5k (up 2.1% from 1Q 2022). Profit margin: 39% (up from 37% in 1Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 56% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 19IBEX Technologies Inc., Annual General Meeting, Jan 25, 2023IBEX Technologies Inc., Annual General Meeting, Jan 25, 2023.Reported Earnings • Nov 16Full year 2022 earnings released: EPS: CA$0.07 (vs CA$0.031 in FY 2021)Full year 2022 results: EPS: CA$0.07 (up from CA$0.031 in FY 2021). Revenue: CA$7.89m (up 49% from FY 2021). Net income: CA$1.67m (up 120% from FY 2021). Profit margin: 21% (up from 14% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 72% per year, which means it is significantly lagging earnings growth.Reported Earnings • Jun 11Third quarter 2022 earnings released: EPS: CA$0.02 (vs CA$0.014 in 3Q 2021)Third quarter 2022 results: EPS: CA$0.02 (up from CA$0.014 in 3Q 2021). Revenue: CA$2.21m (up 51% from 3Q 2021). Net income: CA$569.6k (up 71% from 3Q 2021). Profit margin: 26% (up from 23% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has only increased by 61% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 19Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: CA$0.02 (up from CA$0.012 in 2Q 2021). Revenue: CA$1.83m (up 40% from 2Q 2021). Net income: CA$405.5k (up 63% from 2Q 2021). Profit margin: 22% (up from 19% in 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.Reported Earnings • Dec 17First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: EPS: CA$0.03 (up from CA$0.01 in 1Q 2021). Revenue: CA$1.78m (up 53% from 1Q 2021). Net income: CA$664.6k (up 343% from 1Q 2021). Profit margin: 37% (up from 13% in 1Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.Board Change • Jul 31High number of new directorsDirector Christine Charette was the last director to join the board, commencing their role in 2021.Reported Earnings • Jun 18Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CA$1.47m (down 13% from 3Q 2020). Net income: CA$333.5k (down 47% from 3Q 2020). Profit margin: 23% (down from 37% in 3Q 2020). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 12% per year.Reported Earnings • Mar 21Second quarter 2021 earnings released: EPS CA$0.012 (vs CA$0.001 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CA$1.31m (up 31% from 2Q 2020). Net income: CA$248.5k (up CA$277.5k from 2Q 2020). Profit margin: 19% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Mar 12New 90-day high: €0.23The company is up 50% from its price of €0.15 on 11 December 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.Is New 90 Day High Low • Feb 19New 90-day high: €0.21The company is up 33% from its price of €0.16 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.Is New 90 Day High Low • Feb 16New 90-day high: €0.20The company is up 25% from its price of €0.16 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period.Reported Earnings • Nov 07Full year 2020 earnings released: EPS CA$0.04The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CA$5.21m (up 21% from FY 2019). Net income: CA$965.7k (up CA$2.23m from FY 2019). Profit margin: 19% (up from net loss in FY 2019). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 93% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、IBEX Technologies は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:IBT - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数1/31/20248423N/A10/31/20238412N/A7/31/20237412N/A4/30/20238212N/A1/31/20238122N/A10/31/20228233N/A7/31/20228234N/A4/30/20227233N/A1/31/20226133N/A10/31/20216112N/A7/31/20215111N/A4/30/20215112N/A1/31/20216111N/A10/31/20205122N/A7/31/20205111N/A4/30/20205000N/A1/31/20204-100N/A10/31/20194-100N/A7/31/20194-1-10N/A4/30/20194-100N/A1/31/20195011N/A10/31/20185000N/A7/31/20185000N/A4/30/20185200N/A1/31/20185200N/A10/31/201753N/A1N/A7/31/201753N/A1N/A4/30/201751N/A1N/A1/31/201740N/A0N/A10/31/201640N/A1N/A7/31/201640N/A1N/A4/30/201651N/A2N/A1/31/201651N/A2N/A10/31/201541N/A1N/A7/31/201530N/A0N/A4/30/20153-1N/A0N/A1/31/20153-1N/A0N/A10/31/201440N/A0N/A7/31/201440N/A0N/A4/30/201440N/A0N/A1/31/201440N/A0N/A10/31/201340N/A0N/A7/31/201340N/A0N/A4/30/20134-1N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: IBTの予測収益成長が 貯蓄率 ( 0.6% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: IBTの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: IBTの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: IBTの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: IBTの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: IBTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/04/08 16:51終値2024/04/08 00:00収益2024/01/31年間収益2023/07/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋IBEX Technologies Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Dec 15IBEX Technologies Inc. Provides Earnings Guidance for the Fiscal Year 2024IBEX Technologies Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the fiscal year 2023 range, with continued strong growth in the hemostasis business. Earnings before tax to be in line with the fiscal year 2023.
お知らせ • Apr 12The Common Shares of IBEX Technologies to Be Delisted from TSX Venture Exchange, in Connection with the Completion of the Amalgamation and Effective at the Close of Business on April 11, 2024TSX Venture Exchange has accepted for filing an acquisition agreement dated February 9, 2024 between IBEX Technologies Inc. (the Company) and an arm's length third party (the "Acquirer") pursuant to which the Acquirer acquired all of the issued and outstanding common shares of the Company by way of an amalgamation under the Canada Business Corporations Act (the "CBCA") (the "Amalgamation"). In connection with the completion of the Amalgamation and effective at the close of business on April 11, 2024, the common shares of the Company will be delisted from TSX Venture Exchange.
お知らせ • Apr 09+ 1 more updateBBI Solutions OEM Limited completed the acquisition of IBEX Technologies Inc. (TSXV:IBT) from Milfam LLC, McLean Capital Inc., Paul Baehr and others.BBI Solutions OEM Limited entered into a binding acquisition agreement to acquire IBEX Technologies Inc. (TSXV:IBT) from Milfam LLC, McLean Capital Inc., Paul Baehr and others for CAD 35.5 million on February 9, 2024. BBI will acquire all of the issued and outstanding shares of IBEX at a price of CAD 1.45 per share in cash. Under the amalgamation, each issued and outstanding common share of IBEX will be exchanged for one redeemable preferred share of Amalco, which will immediately be redeemed for CAD 1.45 cash per share. The total consideration is approximately CAD 37.9 million. Upon completion of the amalgamation, shareholders will cease to hold shares of IBEX and IBEX will be delisted from the TSX Venture Exchange. If BBI Solutions termination fee event occurs pursuant to Section 9.2(c)(i) of the acquisition agreement, the BBI Solutions shall pay IBEX the termination fee of CAD 0.97 million and if IBEX termination fee event occurs, IBEX shall pay the BBI Solutions the termination fee of CAD 1.894 million to BBI Solutions in accordance with Section 10.2(b) of the acquisition agreement. The amalgamation is subject to approval by at least two-thirds of the votes cast by IBEX shareholders present in person or represented by proxy and entitled to vote at the Meeting and is subject to third party approval. The Board of Directors of IBEX, after consultation with its financial and legal advisors, has unanimously approved entering into the acquisition agreement. Paul Baehr, Chairman, President and Chief Executive Officer of IBEX, and all of IBEX’s other directors and senior officers, holding in the aggregate approximately 10.39% of IBEX’s outstanding shares, have entered into Support and Voting Agreements with the Purchaser under which they have each agreed irrevocably to support and vote their shares in favour of the amalgamation. In addition, McLean Capital Inc. of Laval, Québec, and entities managed and advised by MILFAM LLC, holding in the aggregate approximately 36.76% of IBEX’s outstanding shares, have entered into similar Support and Voting Agreements with the Purchaser under which they have each agreed irrevocably to support and vote their shares in favour of the Amalgamation. As a result, shareholders holding in the aggregate approximately 47.15% of IBEX’s outstanding shares have entered into Support and Voting Agreements with the Purchaser. The amalgamation was approved by IBEX shareholders at an annual and special meeting held on April 3, 2024. Closing of the amalgamation is expected to take place on April 8, 2024.Fort Capital Partners provided a fairness opinion to the Board of Directors of IBEX in connection with the Amalgamation. Laurel Hill Advisory Group has been retained as IBEX’s shareholder communications advisor and will receive a fee of CAD 0.05 million for its services. Fasken Martineau DuMoulin LLP is acting as legal counsel to IBEX in connection with the amalgamation. Computershare Investor Services Inc. acted as depositary and transfer agent to IBEX.BBI Solutions OEM Limited completed the acquisition of IBEX Technologies Inc. (TSXV:IBT) from Milfam LLC, McLean Capital Inc., Paul Baehr and others on April 8, 2024. In connection with the sale, IBEX has applied for delisting from the TSX Venture Exchange, which is expected to occur on or about April 11, 2024.
お知らせ • Mar 25IBEX Technologies Provides Delisting UpdateIBEX Technologies Inc. has entered into an agreement for the sale of the company. Subject to shareholder approval on April 3, 2024, the transaction is expected to close on April 8, 2024, following which the company will be delisted from the TSX Venture Exchange.
お知らせ • Feb 14+ 1 more updateIBEX Technologies to Delist from TSX-VIBEX Technologies Inc, has announced that it has entered into a binding acquisition agreement dated February 9, 2024 (the "Acquisition Agreement") and related agreements with 15720273 Canada Inc. (the "Purchaser"), a newly incorporated, wholly-owned subsidiary of BBI Solutions OEM Limited ("BBI"), whereby BBI will acquire all of the issued and outstanding shares of IBEX at a price of $1.45 per share in cash. Upon completion of the Amalgamation, shareholders will cease to hold shares of IBEX and IBEX will be delisted from the TSX Venture Exchange.
Reported Earnings • Dec 15First quarter 2024 earnings released: EPS: CA$0.03 (vs CA$0.03 in 1Q 2023)First quarter 2024 results: EPS: CA$0.03 (in line with 1Q 2023). Revenue: CA$2.06m (up 18% from 1Q 2023). Net income: CA$810.3k (up 19% from 1Q 2023). Profit margin: 39% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Dec 15IBEX Technologies Inc. Provides Earnings Guidance for the Fiscal Year 2024IBEX Technologies Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the fiscal year 2023 range, with continued strong growth in the hemostasis business. Earnings before tax to be in line with the fiscal year 2023.
お知らせ • Nov 18IBEX Technologies Inc., Annual General Meeting, Jan 24, 2024IBEX Technologies Inc., Annual General Meeting, Jan 24, 2024.
Reported Earnings • Nov 10Full year 2023 earnings released: EPS: CA$0.16 (vs CA$0.067 in FY 2022)Full year 2023 results: EPS: CA$0.16 (up from CA$0.067 in FY 2022). Revenue: CA$7.49m (down 5.1% from FY 2022). Net income: CA$3.89m (up 133% from FY 2022). Profit margin: 52% (up from 21% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Jun 09New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 26% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (26% accrual ratio). Minor Risk Market cap is less than US$100m (€16.4m market cap, or US$17.7m).
Reported Earnings • Jun 08Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.02 in 3Q 2022)Third quarter 2023 results: EPS: CA$0.03 (up from CA$0.02 in 3Q 2022). Revenue: CA$2.26m (up 2.5% from 3Q 2022). Net income: CA$891.4k (up 56% from 3Q 2022). Profit margin: 39% (up from 26% in 3Q 2022). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 59% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Mar 21Second quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.02 in 2Q 2022)Second quarter 2023 results: EPS: CA$0.003 (down from CA$0.02 in 2Q 2022). Revenue: CA$1.72m (down 6.0% from 2Q 2022). Net income: CA$100.0k (down 75% from 2Q 2022). Profit margin: 5.8% (down from 22% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has increased by 105% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Dec 16First quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.03 in 1Q 2022)First quarter 2023 results: EPS: CA$0.03 (in line with 1Q 2022). Revenue: CA$1.75m (down 1.7% from 1Q 2022). Net income: CA$678.5k (up 2.1% from 1Q 2022). Profit margin: 39% (up from 37% in 1Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 56% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 19IBEX Technologies Inc., Annual General Meeting, Jan 25, 2023IBEX Technologies Inc., Annual General Meeting, Jan 25, 2023.
Reported Earnings • Nov 16Full year 2022 earnings released: EPS: CA$0.07 (vs CA$0.031 in FY 2021)Full year 2022 results: EPS: CA$0.07 (up from CA$0.031 in FY 2021). Revenue: CA$7.89m (up 49% from FY 2021). Net income: CA$1.67m (up 120% from FY 2021). Profit margin: 21% (up from 14% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 72% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Jun 11Third quarter 2022 earnings released: EPS: CA$0.02 (vs CA$0.014 in 3Q 2021)Third quarter 2022 results: EPS: CA$0.02 (up from CA$0.014 in 3Q 2021). Revenue: CA$2.21m (up 51% from 3Q 2021). Net income: CA$569.6k (up 71% from 3Q 2021). Profit margin: 26% (up from 23% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has only increased by 61% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 19Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: CA$0.02 (up from CA$0.012 in 2Q 2021). Revenue: CA$1.83m (up 40% from 2Q 2021). Net income: CA$405.5k (up 63% from 2Q 2021). Profit margin: 22% (up from 19% in 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Dec 17First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: EPS: CA$0.03 (up from CA$0.01 in 1Q 2021). Revenue: CA$1.78m (up 53% from 1Q 2021). Net income: CA$664.6k (up 343% from 1Q 2021). Profit margin: 37% (up from 13% in 1Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.
Board Change • Jul 31High number of new directorsDirector Christine Charette was the last director to join the board, commencing their role in 2021.
Reported Earnings • Jun 18Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CA$1.47m (down 13% from 3Q 2020). Net income: CA$333.5k (down 47% from 3Q 2020). Profit margin: 23% (down from 37% in 3Q 2020). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 12% per year.
Reported Earnings • Mar 21Second quarter 2021 earnings released: EPS CA$0.012 (vs CA$0.001 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CA$1.31m (up 31% from 2Q 2020). Net income: CA$248.5k (up CA$277.5k from 2Q 2020). Profit margin: 19% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Mar 12New 90-day high: €0.23The company is up 50% from its price of €0.15 on 11 December 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Feb 19New 90-day high: €0.21The company is up 33% from its price of €0.16 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Feb 16New 90-day high: €0.20The company is up 25% from its price of €0.16 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period.
Reported Earnings • Nov 07Full year 2020 earnings released: EPS CA$0.04The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CA$5.21m (up 21% from FY 2019). Net income: CA$965.7k (up CA$2.23m from FY 2019). Profit margin: 19% (up from net loss in FY 2019). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 93% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.